These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 26214314)

  • 1. Did α-Synuclein and Glucocerebrosidase Coevolve? Implications for Parkinson's Disease.
    Gruschus JM
    PLoS One; 2015; 10(7):e0133863. PubMed ID: 26214314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease.
    Murphy KE; Gysbers AM; Abbott SK; Tayebi N; Kim WS; Sidransky E; Cooper A; Garner B; Halliday GM
    Brain; 2014 Mar; 137(Pt 3):834-48. PubMed ID: 24477431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocerebrosidase haploinsufficiency in A53T α-synuclein mice impacts disease onset and course.
    Tayebi N; Parisiadou L; Berhe B; Gonzalez AN; Serra-Vinardell J; Tamargo RJ; Maniwang E; Sorrentino Z; Fujiwara H; Grey RJ; Hassan S; Blech-Hermoni YN; Chen C; McGlinchey R; Makariou-Pikis C; Brooks M; Ginns EI; Ory DS; Giasson BI; Sidransky E
    Mol Genet Metab; 2017 Dec; 122(4):198-208. PubMed ID: 29173981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's disease.
    Rockenstein E; Clarke J; Viel C; Panarello N; Treleaven CM; Kim C; Spencer B; Adame A; Park H; Dodge JC; Cheng SH; Shihabuddin LS; Masliah E; Sardi SP
    Hum Mol Genet; 2016 Jul; 25(13):2645-2660. PubMed ID: 27126635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation.
    Fishbein I; Kuo YM; Giasson BI; Nussbaum RL
    Brain; 2014 Dec; 137(Pt 12):3235-47. PubMed ID: 25351739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of Glucocerebrosidase Dysfunction in Parkinson's Disease.
    Chatterjee D; Krainc D
    J Mol Biol; 2023 Jun; 435(12):168023. PubMed ID: 36828270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D409H GBA1 mutation accelerates the progression of pathology in A53T α-synuclein transgenic mouse model.
    Kim D; Hwang H; Choi S; Kwon SH; Lee S; Park JH; Kim S; Ko HS
    Acta Neuropathol Commun; 2018 Apr; 6(1):32. PubMed ID: 29703245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
    Blanz J; Saftig P
    J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in GBA-associated Parkinson's disease--Pathology, presentation and therapies.
    Barkhuizen M; Anderson DG; Grobler AF
    Neurochem Int; 2016 Feb; 93():6-25. PubMed ID: 26743617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-synuclein dimerization in erythrocytes of patients with genetic and non-genetic forms of Parkinson's Disease.
    Papagiannakis N; Koros C; Stamelou M; Simitsi AM; Maniati M; Antonelou R; Papadimitriou D; Dermentzaki G; Moraitou M; Michelakakis H; Stefanis L
    Neurosci Lett; 2018 Apr; 672():145-149. PubMed ID: 29129675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocerebrosidase as a therapeutic target for Parkinson's disease.
    Chen Y; Sam R; Sharma P; Chen L; Do J; Sidransky E
    Expert Opin Ther Targets; 2020 Apr; 24(4):287-294. PubMed ID: 32106725
    [No Abstract]   [Full Text] [Related]  

  • 12. Parkinson's Disease: Glucocerebrosidase 1 Mutation Severity Is Associated with CSF Alpha-Synuclein Profiles.
    Lerche S; Wurster I; Roeben B; Zimmermann M; Riebenbauer B; Deuschle C; Hauser AK; Schulte C; Berg D; Maetzler W; Waniek K; Lachmann I; Liepelt-Scarfone I; Gasser T; Brockmann K
    Mov Disord; 2020 Mar; 35(3):495-499. PubMed ID: 31670439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of β-glucocerebrosidase increases α-synuclein secretion and exosome release in mouse models of Parkinson's disease.
    Papadopoulos VE; Nikolopoulou G; Antoniadou I; Karachaliou A; Arianoglou G; Emmanouilidou E; Sardi SP; Stefanis L; Vekrellis K
    Hum Mol Genet; 2018 May; 27(10):1696-1710. PubMed ID: 29547959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease.
    Parnetti L; Chiasserini D; Persichetti E; Eusebi P; Varghese S; Qureshi MM; Dardis A; Deganuto M; De Carlo C; Castrioto A; Balducci C; Paciotti S; Tambasco N; Bembi B; Bonanni L; Onofrj M; Rossi A; Beccari T; El-Agnaf O; Calabresi P
    Mov Disord; 2014 Jul; 29(8):1019-27. PubMed ID: 24436092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.
    Wong YC; Krainc D
    Mov Disord; 2016 Nov; 31(11):1610-1618. PubMed ID: 27619775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.
    Johnson PH; Weinreb NJ; Cloyd JC; Tuite PJ; Kartha RV
    Mol Genet Metab; 2020 Feb; 129(2):35-46. PubMed ID: 31761523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson's disease patients.
    Parnetti L; Paciotti S; Eusebi P; Dardis A; Zampieri S; Chiasserini D; Tasegian A; Tambasco N; Bembi B; Calabresi P; Beccari T
    Mov Disord; 2017 Oct; 32(10):1423-1431. PubMed ID: 28843015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine.
    Blandini F; Cilia R; Cerri S; Pezzoli G; Schapira AHV; Mullin S; Lanciego JL
    Mov Disord; 2019 Jan; 34(1):9-21. PubMed ID: 30589955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid fatty acids in glucocerebrosidase-associated Parkinson's disease.
    Schmid SP; Schleicher ED; Cegan A; Deuschle C; Baur S; Hauser AK; Synofzik M; Srulijes K; Brockmann K; Berg D; Maetzler W
    Mov Disord; 2012 Feb; 27(2):288-92. PubMed ID: 22021190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acid ceramidase inhibition ameliorates α-synuclein accumulation upon loss of GBA1 function.
    Kim MJ; Jeon S; Burbulla LF; Krainc D
    Hum Mol Genet; 2018 Jun; 27(11):1972-1988. PubMed ID: 29579237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.